BD (NYSE:BDX) announced that it expanded its Class I voluntary recall for its Alaris Pump Module model 8100 infusion system.
Our sister site, Drug Delivery Business News, reports today that the expansion builds on a voluntary recall expanded earlier this year, informing customers of worst-case performance instances. Under certain cases, the pump, when used with a subset of compatible infusion sets, fails to perform as compared to the performance described in its user manual, according to a news release.
BD’s update includes an expansion of 15 additional impacted pump infusion sets included in the recall, plus new corrective actions and risk information. The company discontinued the 15 additional sets but they may remain in inventory based on their expiration date.
Get the full story at our sister site, Drug Delivery Business News.
